Editact Therapeutics is a biotechnology and pharmaceutical company headquartered in Hong Kong. Dedicated to revolutionizing gene editing technologies and human health, it is pioneering first-in-class “one-for-many” genome editing solutions to familial diseases. Our first drug leads aim to target and treat Familial Alzheimer’s disease (FAD). Editact is committed to addressing unmet medical needs through genome editing, thus offering a new lease on life for patients with inherited and otherwise incurable diseases.
Company Details
- Address
- Hong Kong, Hk
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Hong Kong
Editact Therapeutics Ltd. Questions
Editact Therapeutics Ltd.'s LinkedIn profile is https://www.linkedin.com/company/editact
Editact Therapeutics Ltd.'s industry is
Biotechnology Research
Editact Therapeutics Ltd.'s top competitors are
Alcarbo Technologies Limited,
Advanced Biomedical Instrumentation Centre,
Syngular Technology,
上海赛笠生物科技有限公司,
Allegrow Biotech,
Lw Consulting,
Green Vigor Limited,
The Cell Fate Engineering And Therapeutics Laboratory,
Innocellular,
Syngar Technologies.
Editact Therapeutics Ltd.'s categories are Biotechnology Research
